Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer-Reference-Cited by-同舟云学术

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

Published:2018-01-19 Issue:7 Volume:110 Page:726-733
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Lindström Linda S¹,Yau Christina²³,Czene Kamila⁴,Thompson Carlie K²,Hoadley Katherine A⁵,van't Veer Laura J⁶⁷,Balassanian Ron⁶,Bishop John W⁸,Carpenter Philip M⁹¹⁰,Chen Yunn-Yi⁶,Datnow Brian¹¹,Hasteh Farnaz¹¹,Krings Gregor⁶,Lin Fritz¹⁰,Zhang Yanhong⁸,Nordenskjöld Bo¹²,Stål Olle¹²,Benz Christopher C²³,Fornander Tommy¹³,Borowsky Alexander D⁸,Esserman Laura J²,

Affiliation:

1. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

2. Department of Surgery, University of California San Francisco, San Francisco, CA

3. Buck Institute for Research on Aging, Novato, CA

4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

5. Department of Genetics, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC

6. Department of Pathology, University of California San Francisco, San Francisco, CA

7. Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA

8. Center for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California Davis, Davis, CA

9. Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA

10. Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA

11. Department of Pathology and Laboratory Medicine, University of California San Diego, La Jolla, CA

12. Department of Clinical and Experimental Medicine and Department of Oncology, Linköping University, Linköping, Sweden

13. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

Funder

Swedish Research Council

FORTE

Swedish Cancer Society

Stockholm Cancer Society

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/7/726/25124810/djx270.pdf

Reference36 articles.

1. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world;Kamangar;J Clin Oncol.,2006

2. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers;Pichon;Br J Cancer.,1996

3. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials;Early Breast Cancer Trialists' Collaborative Group;Lancet.,2011

4. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the International Breast Cancer Study Group trials I to V;Colleoni;J Clin Oncol.,2016

5. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901;Sheppard;J Clin Oncol.,2014

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer;Virchows Archiv;2024-01-13

2. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer;npj Breast Cancer;2024-01-02

3. Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance;European Journal of Cancer;2024-01

4. Fluorine-18-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies—AJR Expert Panel Narrative Review;American Journal of Roentgenology;2023-12-20

5. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity;EMBO Molecular Medicine;2023-10-30